Merck’s Keytruda has been hitting its trial targets so often, it’s tempting to think it can't miss. But Tuesday’s data in liver cancer shows it can.
A CDMO that has made a habit of snapping up Big Pharma’s discarded manufacturing plants has put a former AstraZeneca plant into bankruptcy.
Activist hedge fund Starboard Value may be trying to thwart the $74 billion buyout of Celgene by finding a buyer for BMS, some analysts speculate.
Allergan said it'll support an investor resolution to split up its CEO and chairman roles as part of its next leadership change.
Insulin giants have to face class-action claims that their rising insulin prices and behind-the-scenes rebates break consumer protection laws.
Two Big Pharmas are racing toward a new indication in kidney cancer, but thanks to new data from Merck, it may not matter who gets there first.
Novartis biotech AveXis will invest another $60 million and hire another 200 workers for the site it is building in Durham, North Carolina.
As Bayer anted up on Viktravi, Roche nabbed FDA priority review for its potential rival, entrectinib, eyeing an FDA nod by August.
Just days after bad news about manufacturing wreaked havoc with Dr. Reddy’s shares, the drugmaker was able to report something positive.
Pfizer’s Xeljanz topped AbbVie's Humira in a rare bypass of the usual No. 1 monthly TV commercial pharma spender.
